



Some isatin and indole derivatives, which are Schiff and Mannich bases, as well as related hydrazones, have shown a broad spectrum of biological activity and are used in the treatment of cardiac ischemia, arrhythmia, stenocardia, and as antidepressants.<sup>21–24</sup> Isatin itself blocks the natriuretic peptide receptor and is quite effective as antidepressant, which is likely caused by the biological action of its metabolite tribulin on the human nervous system.<sup>25</sup>

Publications from recent years describe the synthesis of new isatin derivatives, which are effective inhibitors of rhinovirus and coronavirus proteases,<sup>26</sup> as well as the reverse transcriptase of HIV. Isatin derivatives obtained by conjugation with other biologically active compounds were identified as effective inhibitors of tyrosinases, various kinases, guanylate cyclase – enzymes that play important role in the development of tumors and myocardial ischemia, as well as inhibited the cyclin-dependent kinase – a key regulator of cell division.<sup>27,28</sup> The same publications also described the high spasmolytic activity of isatin itself, its inhibitory activity against xanthine oxidase, and the potential use of such compounds as anticancer drugs: derivatives of indigo and indirubin were found among compounds isolated from rats with cancer. The antitumor effects of indole and isatin derivatives have been reviewed in the literature.<sup>10,11</sup>


We will focus on the reactivity of isatin derivatives towards phosphorus compounds, a topic that has been partially covered by an earlier review (references until 1999) by Gurevich and Yaroshevskaya,<sup>29</sup> devoted to indole chemistry. The introduction of phosphorus-containing fragment into molecules of biologically active compounds can be considered as a powerful technique for designing new drugs, because it may lead to new types of biological activity, as well as improve the transport through cell membranes. On the other hand, the use of organophosphorus compounds as reagents for the modification of isatin derivatives enables various valuable synthetic transformations of the isatin moiety. Besides that, the use of phosphorus compounds as organocatalysts offers possibilities for involving isatin derivatives into a range of multicomponent reactions. For these reasons, we consider it necessary to systematize and generalize in this review the reported reactions of isatins with phosphorus compounds, published between 1966 and 2014. Older publications are referred to only when relevant to the current state of art in this field.

### ISATIN DERIVATIVES IN REACTIONS WITH THREE - AND FOUR-COORDINATE PHOSPHORUS COMPOUNDS

One of the best known and widely used reactions of isatin derivatives with phosphorus compounds is the Abramov reaction. The influence of substituents at the phosphorus atom on the synthetic outcome in reaction with isatin (**1a**) was studied by using 4-tolyl- and 1-naphthylphosphonous acids, as well as dimethyl- and diethyl phosphites.<sup>30</sup> The reactions were performed in methanol at equimolar ratio of reagents, in the presence of sodium methoxide catalyst, by refluxing for 0.5–1 h. The

phosphorus-containing 2-indolinones **2** were obtained in 77–93% yields (Scheme 1).


Scheme 1



R, R<sup>1</sup> = OMe, OMe; OEt, OEt; OH, 4-MeC<sub>6</sub>H<sub>4</sub>; OH,  $\alpha$ -naphthyl


The preparation of phosphorus-containing 2-indolinone derivatives has also been described.<sup>31</sup> Thus, Abramov reaction was performed by treating 5-bromoisatin (**1b**) with diethylphosphorous acid in ethanol, in the presence of sodium ethoxide, yielding compound **3**, which was further transformed by Arbuzov reaction in the presence of nickel bromide to the diphosphonate **4** (Scheme 2).

Scheme 2




The isatins **1c,d** with substituents at position 5 reacted with various diesters of phosphorous acid, forming hydroxyphosphonates **5**, **6**<sup>32–36</sup> (Scheme 3). The yield of reaction products was increased by using ultrasound,<sup>32</sup> but the yields were also strongly affected by the choice of solvent and reaction temperature. Thus, performing the reaction in chloroform at room temperature for 15 min gave compounds **5** in 38% yield, in ethanol – 33%; without solvent at room temperature increased the yields to 69%, while performing the reaction at 45°C gave up to 92% yield. The formation of hydroxyphosphonates **6** in high yields (89–94%) was also promoted by  $\beta$ -cyclodextrin in aqueous medium for 1–4 h.<sup>33</sup> In subsequent works the yield of products **6** was optimized by using various catalysts: quinine (the reaction was performed at 0°C in dichloromethane, catalyst content 20%, yields of compounds **6** were 33–99%),<sup>34</sup> ZnO nanopowder (the highest result was achieved by adding 25% of nanopowder under solvent-free conditions, the reaction was performed for 45 min, resulting in up to 95% yields of compounds **6**),<sup>37</sup> copper acetate (the highest yields of compounds **6** (91%) were achieved by performing the reaction in methanol, while the enantiomeric excess of the obtained chiral hydroxyphosphonate was also high (*ee* 83%), due to the application of chiral bis(oxazoline) ligands).<sup>38</sup> Synthesis of  $\alpha$ -hydroxyphosphonates in 82–92% yields was achieved in PEG 400 at 50°C for 10 h.<sup>35</sup> A phosphonate–phosphate rearrangement and the <sup>31</sup>P spectroscopic study of hydroxyphosphonate obtained from 5-methylisatin have been described.<sup>36</sup>

Scheme 3




Abramov reaction with subsequent phosphonate-phosphate rearrangement was performed with *N*-allylisatin (**1c**). The process was catalyzed by lanthanum amide complex  $[(Me_3Si)_2N]_3Ln(\mu-Cl)Li(THF)_3$ , and led to the formation of (1-allyl-2-oxoindolin-3-yl)diethylphosphate (**7**)<sup>39</sup> in up to 93% yield (Scheme 4).

Scheme 4




The analysis of a considerable number of publications regarding the interaction of isatin with phosphorus(III) compounds showed that the phosphorus compounds reacted predominantly at the ketone carbonyl group (position 3 of the isatin moiety). Thus, it was shown that trialkylphosphites and phosphonites reacted in refluxing benzene with isatin (**1a**) or its 1-acetyl derivative **1d** and 5-bromo derivative **1b**, forming unstable 1,3,2-dioxaphospholes **8** in 50–92% yields, which isomerized in ethanol solution to the respective phosphoryl compounds **9**<sup>30,41,42</sup> (Scheme 5).

Scheme 5




Taking into account the effect of substituent at the phosphorus atom in phosphorous acid derivatives on the stability of the obtained spiroposphoranes, it was proposed that including a phosphorus atom in a five-membered dioxaphospholane ring may lead to the stabilization of spiroposphorane structure. Indeed, 2-dialkylaminodioxaphospholanes reacted with 2 mol of isatin (**1a**) or 1-methylisatin (**1e**) in benzene and produced the more stable spiroposphoranes **10** in 36–80% yields,<sup>43,44</sup> in agreement with the published data.<sup>30,41</sup> Besides that, it was shown that acyclic phosphites can also react along the route leading to spiroposphoranes **11**, giving 36–78% yields (Scheme 6).<sup>44</sup>

Scheme 6




Similarly to cyclic and acyclic phosphites, pyrocatechol chlorophosphite in benzene medium reacted with isatin (**1a**) at the ketone group,<sup>45</sup> forming 3-chloro-3-phenylenedioxaphospholyindolin-2-one (**12**) in 79% yield, which was easily oxidized in air to the cyclic phosphonate **13** in nearly quantitative yield. However, the same reaction in the presence of triethylamine occurred along the route of *N*-phosphorylation, forming the isatin derivative **14**, which also was easily converted to the respective phosphate **15** in 85% yield (Scheme 7).

Scheme 7




Substitution of chlorine atom with diethylamino group in the molecule of catechol phosphite derivative turned the reaction of phosphole **16** with 1-propylisatin (**1f**) towards a different direction, where the only product formed was spiroposphorane derivative **17** in 73% yield, with structure established by X-ray structural analysis<sup>46</sup> (Scheme 8).

Scheme 8




Phosphorylation of the isatin system at nitrogen atom was studied for the case of unsubstituted isatin (**1a**) with diphenylchlorophosphine. Isatin (**1a**) was shown to undergo phosphorylation at the nitrogen atom and position 3 of the heterocycle upon refluxing in xylene for 2–3 h, forming the derivative **18** with two phosphorus atoms with coordination numbers of 3 and 4, while 1-acetylisatin (**1d**) under the same conditions produced the indole-containing phosphine oxide **19** in 60% yield (Scheme 9).<sup>47</sup>

Scheme 9



At the same time, it was found that isatin **1g**, containing two hydroxyl groups in the substituent at nitrogen atom, reacted with dichlorophosphite and formed only the cyclic phosphite **20** with preserved ketone carbonyl group (Scheme 10).<sup>29</sup>


Scheme 10




It was shown in another report that prolonged heating of triphenylphosphine and isatin gave a mixture of 3-(triphenylphosphorylidene)-2,3-dihydro-1*H*-indol-2-one (**21**) and isoindigo (**22**) in moderate yields (44 and 49%, respectively, Scheme 11).<sup>48</sup>

We proposed in 2008 a simpler and more effective method for the preparation of isoindigo derivatives **23** in nearly quantitative yields, by using hexaethyltriimidophosphite instead of triphenylphosphine.<sup>49</sup> We further extended this method to more complex, functionalized isatin derivatives (Scheme 12).<sup>50–57</sup>

Scheme 11




Scheme 12




It was considered worthwhile to establish the influence of phosphorus substituents on the results of this reaction. For this purpose, amidophosphites **24**, **25** were reacted with propylisatin (**1f**) (Scheme 13).<sup>45</sup> However, in contrast to hexaethyltriimidophosphite, the amidophosphites **24** and **25** reacted quite slowly, but the target compound isolation was complicated due to difficulty of their purification from the respective amidophosphates (80 and 77% yields, respectively).

Scheme 13



Scheme 14






the carbon atom at position 3 of the heterocycle, followed by P–C bond cleavage and the formation of methyl indolylacetate **38** (Scheme 18).


The cyclic indolophosphates **40** were obtained by the action of sodium in THF on 1-methylisatin (**1e**), followed by treatment of dianion **39** with dichlorophosphate (Scheme 19).<sup>64</sup>

Scheme 19




The ketone group of isatin derivatives **1a,d,e,l,m** could react by addition of diazomethyl phosphinate **41**, forming  $\beta$ -hydroxyphosphinates **42a–e**, which underwent ring expansion upon treatment with hydrochloric acid, forming the phosphorus-containing quinolones **43a–e** (Scheme 20).<sup>65,66</sup>

Scheme 20




This addition reaction of  $\alpha$ -diazophosphoryl compounds **44** at position 3 of isatin with subsequent ring expansion was also applicable to derivatives of indane-2,3-dione, benzofuran-2,3-dione, and pyrrole-2,3-dione, and was used to obtain compounds **45**, **46**. The reaction with benzothiophene-2,3-dione occurred at position 2 and produced  $\alpha$ -diazophosphonates **47**.<sup>65</sup> 3-Diazopyrrolidine-2,4,5-trione reacted with triphenylphosphine at the diazo group, forming imine **48** (Scheme 21).<sup>67</sup>

Scheme 21



Isatin (**1a**) was recently shown to react easily with diphenyl- or dialkyl(2-methyl-4-oxopent-2-yl)phosphine oxides **49**, forming Pfitzinger reaction products – 4-quinolinecarboxylic acid derivatives **50**, containing a phosphine oxide group at position 2 (Scheme 22).<sup>68</sup>


Scheme 22



The reactions occurring between isatins **1a,b** and derivatives of phosphinic and phosphonic acids **51** with activated methylene group have been described in publications.<sup>29,69–71</sup> Thus, phosphorylacetic acid, phosphorylaceton, phosphorylacetaldehyde, phenothiazine-containing *N*-acylphosphonates, 2-(phosphorylmethyl)benzimidazole, and 2-(phosphorylmethyl)benzothiazoline reacted with isatins **1a,d**, forming either phosphorus-containing structures **52** or easily polymerizable ylidenes **53**, which did not contain phosphorus (Scheme 23).

Among compounds **53** thus obtained, we should note a derivative with  $\text{R} = \text{OMe}$  and  $\text{R}^1 = \text{C}_{12}\text{H}_{25}$ , which was identified as inhibitor of phosphatase Cdc25 – a key link in the development of oncological diseases.<sup>72</sup> The interaction between *N*-(diethoxyphosphorylacetyl)phenothiazines containing an activated methylene group and isatin (**1a**) was found

Scheme 23




to lead to the formation of phosphorus-containing compound with the phenothiazine pharmacophore fragment.<sup>71</sup>

The high reactivity of ketone carbonyl group in isatin derivatives motivated some studies where these compounds were used in Wittig reactions. For example, the reaction of isatin (**1a**) with (cyanomethylidene)triphenylphosphorane resulted in the formation of electron-deficient oxindole **54** as a mixture of *E*- and *Z*-isomers, which further reacted with trialkylphosphites, forming dialkyl[cyano(2,3-dihydro-2-oxo-1*H*-indol-3-yl)methyl]phosphonate **55** and isomeric bis(indole)-containing cyclic phosphonates **56** (Scheme 24).<sup>73</sup>


Osman and coworkers assumed that the initial reaction occurred between compound **54** and trialkylphosphite, followed by hydrolysis.<sup>74</sup> In our opinion, taking into account the facile hydrolysis of trialkylphosphites, the first step likely involved the formation of dialkylphosphite, followed by Pudovik reaction with compounds **54**, forming structures **55** and **56** (Scheme 24).

Scheme 24




It has been shown that isatin (**1a**) reacts with an ylide containing a carboxylate substituent, producing a high yield of the ylidene compound **57**.<sup>74,75</sup> Similar compounds have also been described in patents as drugs for gastrointestinal conditions, inhibitors of tyrosine kinases and cyclin-dependent kinases, compounds with activity against various tumor cells and HIV (Scheme 25).<sup>77–79</sup>

Scheme 25




$\gamma,\gamma$ -Dimethylallylphosphonium bromide was also used in the Wittig reaction with isatin (**1a**), forming *E*- and *Z*-isomers of alkene **58** (Scheme 26).<sup>79</sup>

Scheme 26




Several more examples of Wittig reactions using phosphonium salts for the synthesis of isatin ylidene derivatives **59–63** have been reported (Scheme 27).<sup>80–84</sup>

Scheme 27




An unusual example of Wittig reaction was the interaction of isatin with chloromethyltriphenylphosphonium iodide, leading to two products: vinylchloride derivative **64** and *gem*-dichloroethene derivative **65** (Scheme 28).<sup>81</sup>

Scheme 28




In contrast to the reaction leading to compound **59**, interaction of the Wittig reagent **66**, containing an aniline fragment, with isatin (**1a**) in acidic medium initially produced the respective imine **A**, which then cyclized in basic medium to spiroindole **67** (Scheme 29).<sup>85</sup>

Scheme 29




1-Alkyl- and 1-acylisatins reacted with dimethyl (triphenylphosphoranylidene)succinate (**68**), forming (2-oxoindolin-3-ylidene)succinate derivatives **69** in low yields<sup>86</sup> (reaction with 1-methylisatin (**1e**) is shown in Scheme 30).

Scheme 30




The indolespirocyclopropane systems **71** were formed by interaction of 1-methylisatin (**1e**) with various triphenylphosphonium salts through intermediate ylidenes **70** (Scheme 31).<sup>87</sup>

Scheme 31




A Wittig reaction of isatin (**1a**) with (ethoxycarbonylmethylidene)triphenylphosphorane with subsequent [1+2] cycloaddition reaction of (isopropylidene)triphenylphosphorane to compound **72a** gave a spirocyclopropane derivative of indolin-2-one (**73**).<sup>88</sup> Reactions of isatins **1a,b** with (acylmethylidene)triphenylphosphoranes in ethanol at room temperature occurred analogously, forming compounds **72** in high yields (Scheme 32).<sup>89</sup>

Scheme 32




Scheme 33



At the same time, reaction of 1-acetyl-5-bromoisatin (**1n**) under the same conditions gave not only the respective compound **74**, which was isolated as Z-isomer, but also the spirocyclic compound **75** (Scheme 33).<sup>90</sup>

Nevertheless, it was shown by Jiang and coworkers<sup>91</sup> that the same ylide reacted with 5-bromoisatin (**1b**), giving only compound **72b** as a mixture of Z- and E-isomers, which were further converted to cyclopropanes **76** by the action of diazomethane. Analogous synthesis of ylide derivatives of isatins was described in another work (Scheme 34).<sup>92</sup>


Scheme 34



Isatin derivatives reacted with  $\alpha$ -carbonyltriphenylphosphoranes **77**, resulting in the formation of isatin ylide compounds **78**.<sup>93</sup> Different results were obtained from the reaction of isatin with phosphorus ylide **79**, containing an electron-withdrawing carboxycarbonyl fragment; the process involved lactam carbonyl and led to the formation of 2-ylidene-substituted derivative **80**. (Triphenylphosphinyldene)pyruvic acid hydrazide (**81**) reacted in the role of N-nucleophile with isatin (**1a**), leading to hydrazone **82** (Scheme 35).



Scheme 35




The preparation of cyclic phosphorus-containing isatin derivative **83** in the Wittig reaction through the unusual cumulenylidene intermediate **C** has been described,<sup>94</sup> and involved using 2 equiv of triphenylphosphorane. The first triphenylphosphorane molecule acted as a nucleophile, attacking with its anionic center the carbon at position 3 of heterocycle, followed by phosphorus attacking the oxygen atom; then through the stage of oxaphosphethane **B** and subsequent elimination of triphenylphosphine oxide a molecule of cumulenylidene **C** was formed. A second triphenylphosphorane molecule added regioselectively at the central C=C double bond of cumulenylidene **C** according to the [2+2] cycloaddition mechanism, finally leading to the formation of cyclic product **83** (Scheme 36).


A three-component interaction between the Wittig reaction product obtained from isatin (**1a**) and ylides (ylidene derivative **84**), amines, and acetoacetic esters led to the formation of spiranes **85**. The yields of compounds **85** strongly depended on the solvent used. The best result (80% yield) was obtained by refluxing the reaction mixture in methanol for 3 h (Scheme 37).<sup>95</sup>

The same approach (through the formation of intermediate ylidene derivatives of isatins) was used in another work,<sup>96</sup> where 1,2-diaminoarenes were converted to derivatives of quinoxaline, 5-azaquinoxaline **86**, and oxindole **87** (Scheme 38).


Scheme 36



Scheme 37




Scheme 38



$R = \text{H, Me}; R^1 = \text{H, Me, Cl, NO}_2; R^2 = \text{H, Br}; X = \text{CH, N}$

The method proposed for obtaining of spiro[indolin-3,6'-[1,3]thiazinanes] **88** involved reacting the ylidene intermediate with dithiocarbamate, which was generated from carbon disulfide and amine (Scheme 39).<sup>97</sup>


Scheme 39



$R = \text{Ph, 2-ClC}_6\text{H}_4, 4\text{-ClC}_6\text{H}_4, 4\text{-MeC}_6\text{H}_4, 4\text{-MeOC}_6\text{H}_4, \text{-CH=CH}_2;$   
 $R^1 = \text{H, Br}$


Compound **90a**, as an analog of marine metabolites, was synthesized from 4,5-disubstituted isatin **89** by a sequence of several reactions, including Wittig reaction and chlorination, in 74% yield (Scheme 40).<sup>98,99</sup> The treatment of compound **90a** first with aqueous HI and then with CF<sub>3</sub>COOH produced also the analogous compounds **90b,c**.

Scheme 40




An aza-Wittig reaction of isatin derivatives with (*tert*-butoxycarbonylaza)triphenylphosphorane, followed by treatment of the iminoisatin intermediate **91** with trimethylsilyl cyanide in hexafluoroisopropanol (Strecker reaction) gave the *gem*-aminonitrile **92**.<sup>100</sup> The range of imines accessible by this procedure was extended by Yan and coworkers,<sup>101</sup> who used various azaphosphoranes as starting materials (Scheme 41).

Scheme 41




1,3,4-Oxadiazole derivatives **94** were obtained by interaction of isatins **1a,o** with azaphosphorane **93** containing an isocyanide fragment, and aromatic acids.<sup>102</sup> The process included addition of isonitrile carbon atom to isatin and subsequent aza-Wittig reaction (Scheme 42).

Scheme 42




Isatins also easily participate in Horner–Wadsworth–Emmons reactions, which was demonstrated for the case of bis(diethoxyphosphoryl)methane,<sup>103</sup> using isatin derivatives substituted both at the nitrogen atom and in the aromatic ring, and resulting in the preparation of a series of indole-containing vinylphosphonates **95** (Scheme 43).

Scheme 43




Some more complex β-ketophosphonates **96** were also used in this reaction, leading to the product of condensation at position 3 of isatin (**1a**), namely, compound **97** (Scheme 44).<sup>104,105</sup>

Scheme 44



Analogous reactions with certain isatin derivatives were also observed for 5-(2,4-dioxaimidazolidino)phosphonate (hydantoinphosphonate), resulting in the formation of (*Z*)-5-(2-oxoindolin-3-ylidene)imidazolidine-2,4-diones **98** (Scheme 45).<sup>106</sup>


Scheme 45



One of the methods for introduction of phosphorus-bearing fragments into isatin derivatives is the reaction of phosphorus-containing carboxyhydrazides with isatin. For example, hydrazones **101** were obtained from 1,3,2-dioxaphospholane **99** (a derivative of tartaric acid dihydrazide) and isatin (**1a**) through the intermediate compounds **100**, followed by aminomethylation according to Mannich (Scheme 46).<sup>107,108</sup> These compounds showed high antiviral, antifungal, antibacterial, and hypotensive activity.

The preparation of 2-(diphenylphosphino)-*N*'-(2-oxoindolin-3-ylidene)acetohydrazide **102** from isatin (**1a**) was described by Bagrov and co-authors.<sup>109</sup> Remarkably, the phosphorus atom did not participate in the reaction in this

Scheme 47



case – the hydrazone **102** was formed in 78% yield (Scheme 47).


### REACTIONS OF ISATIN DERIVATIVES WITH PHOSPHORUS COMPOUNDS IN THE PRESENCE OF A THIRD COMPONENT

The overview given above regarding isatin reactions with phosphorus compounds showed that in many cases P(III) compounds initially formed 1,3-dipoles, which could further interact with suitable dipolarophiles. On the other hand, isatin itself may serve as a dipolarophile when 1,3-dipole is generated from P(III) derivative and an unsaturated compound, such as acetylenedicarboxylate. Both of these approaches have been described in publications that we review in this section. The interest towards such transformations is motivated not only by the access to new heterocyclic and acyclic isatin derivatives, but also by the possibilities for obtaining various metal complexes.

The most studied reactions of this type are those of isatin derivatives with triphenylphosphine in the presence of unsaturated organic reagents. For example, it was shown that reaction of 1-substituted isatins **1e,h,p-r** with triphenylphosphine in the presence of acetylenedicarboxylic esters produced high yields of  $\gamma$ -spirolactones **103**, containing an indolinone fragment.<sup>110–112</sup> The interaction of acetylenedicarboxylate and triphenylphosphine initially gave the bipolar ion **D**, the anionic part of which readily attacked the carbonyl group of isatin, forming zwitterion **E**. The latter underwent an intramolecular attack by alkoxide ion on the carbonyl group, followed by elimination of triphenylphosphine (bipolar ions **F** and **G**) (Scheme 48).

It has been established in another work<sup>113</sup> that the process described above did not occur unequivocally, because the synthesis of spiranes **103** was accompanied by the formation of phosphoranes **104**. Such an outcome of this reaction was partially caused by the presence of isopropyl substituent in acetylenedicarboxylate molecule,

Scheme 46




Ar = Ph, 4-MeC<sub>6</sub>H<sub>4</sub>, 4-ClC<sub>6</sub>H<sub>4</sub>, 4-BrC<sub>6</sub>H<sub>4</sub>, 4-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>; X = NH, O, NMe

and the cycloaddition reaction of betaine **A** as 1,3-dipole with the carbonyl group of isatin. The reaction with ethyl propiolate also occurred analogously, leading to phosphorane **105** (Scheme 49).


The formation of an unusual bipolar product **106** has been described.<sup>114–116</sup> Apparently, isatin (**1a**) in this case reacted as NH acid and added to the zwitterionic intermediate **H**, forming a bipolar ion **I**, which was decarboxylated to the final product **106** (Scheme 50).

Scheme 50




More detailed information about the resonance structures of zwitterions of analogous structure (for example, compound **107**) has been published by Baharfar and co-authors,<sup>117</sup> based on NMR spectroscopy and thermal analysis (Scheme 51).

Scheme 51




Nair and coworkers<sup>118</sup> performed the reaction of isatins **1c,e,h,p** with triphenylphosphine also in the presence of dialkylazodicarboxylate. The reaction gave 56–86% yields of the respective spirooxadiazolines **108**, one of which was unequivocally identified by X-ray structural analysis. This reaction occurred through the zwitterionic intermediate **J** (Mitsunobu reaction intermediate), the N-anionic center of which attacked the carbonyl group of isatin, forming the bipolar ion **K**. The latter reacted by O-anion attack on the COOR<sup>1</sup> carbonyl group, leading to the Wittig reaction intermediate **L**, from which triphenylphosphine oxide was eliminated (Scheme 52).


Scheme 48



Scheme 49




Scheme 52




The result of similar three-component reactions was found to depend also on the nature of substituent at the phosphorus atom. Thus, trialkyl- or triarylphosphites, which are less nucleophilic than triphenylphosphine, reacted with isatin **1a** in the presence of acetylenedicarboxylate not at the ketone, as described above, but at the nitrogen atom of heterocycle,<sup>119</sup> forming the respective isatinylphosphorylsuccinates **109**. Thus, the bipolar ionic intermediate attacked the more acidic proton at the nitrogen atom, which was absent in the *N*-substituted isatin derivatives described above.<sup>110–113,118</sup> Trialkylphosphite initially reacted with acetylenedicarboxylate and gave the zwitterionic intermediate **M**, which added to isatin, and the adduct was hydrolyzed during the chromatographic separation of reaction products (Scheme 53).

Scheme 53



We should also mention within this review a work<sup>120</sup> describing the reaction of isatin (**1a**) with triphenylphosphine in the presence of metal chloride. Such a three-component reaction resulted in complexes **110** that showed good solubility in polar solvents. Similar complexes of isatin, where both carbonyl groups are coordinated with metal, are quite rare (Scheme 54).

Scheme 54




A three-component reaction of isatins with malonodinitrile and dialkylphosphites in the presence of zinc oxide nanopowder has been described in recent publications.<sup>121–123</sup> Malonodinitrile initially formed an ylidene derivative **111**, followed by addition of dialkylphosphite (Pudovik reaction), forming derivatives **112** (Scheme 55).

For the case of reaction between isatin (**1a**), diethylphosphite, and benzylamine, the catalytic activity of tetra(*tert*-butyl)phthalocyanine complex (PhcAlCl) was investigated. Two competing processes were shown to occur in this case – the formation of aminophosphonate **113** (Kabachnik–Fields reaction) and hydroxyphosphonate **114** (Abramov reaction) (Scheme 56).


The reaction of 1-methylisatin (**1e**) with hexamethyl-triamidophosphite in the presence of nitrosobenzene led to the formation of the respective nitron, which gave the spiroisoxazolidine **115** upon treatment with allyl bromide in 64% yield and 1:1 diastereomer ratio (Scheme 57).

A three-component reaction of 1-alkylisatins **116** with hexaethyltriamidophosphite in the presence of fullerene C<sub>60</sub><sup>126,127,129</sup> gave 20–47% yields of methanofullerenes **117** (Scheme 58). Experimental solar cells based on compounds **117** showed an efficiency in excess of 1%.<sup>128,130</sup>


Scheme 56




Scheme 57



Scheme 58




Scheme 55



Compounds <b>111</b> , <b>112</b>	a	b	c	d	e	f	g	h	i	j	k	l	m	n	o	p	q	r	s	t
R <sup>1</sup>	H	Bn	Me	H	H	H	Bn	Me	Et	H	H	Me	H	Bn	Me	Et	H	H	Me	Me
R <sup>2</sup>	H	H	H	NO <sub>2</sub>	Br	H	H	H	H	NO <sub>2</sub>	Br	Br	H	H	H	H	NO <sub>2</sub>	Br	Br	NO <sub>2</sub>
R <sup>3</sup>	Et	Et	Et	Et	Et	Me	Me	Me	Me	Me	Me	Me	<i>i</i> -Pr	<i>i</i> -Pr	<i>i</i> -Pr	<i>i</i> -Pr	<i>i</i> -Pr	<i>i</i> -Pr	<i>i</i> -Pr	<i>i</i> -Pr

Scheme 59



### PHOSPHORUS COMPOUNDS AS CATALYSTS FOR REACTIONS OF ISATINS


Phosphorus(III-V) compounds are widely used in synthesis as nucleophilic (P(III) derivatives) and electrophilic (P(IV,V) derivatives) catalysts. In this section, we consider several publications of key importance, where phosphorus compounds have been used to catalyze synthetic transformations of isatins. For example, amines and phosphines can be used as nucleophilic catalysts in the Morita–Baylis–Hillman reaction – one of the current methods for the formation of C–C bond between  $\alpha$ -position of activated alkenes and aldehydes. Derivatives of 3-R,R<sup>1</sup>-methyleneindolin-2-ones and isatin were introduced into reaction with allenyl carboxylates and ethynyl ketones where phosphines were used as nucleophilic catalysts, and the products were various indole-containing spirocyclic compounds **118**, **119**.<sup>131–134</sup> We should note that the reaction gave different results depending on the nature of the base: the use of DABCO led to the formation of spirane **119**, while spirane **118** was obtained when methyl-diphenylphosphine was used. Mohammadi and co-authors<sup>135</sup> linked the formation of spirane **118** with the presence of zwitterion **N** in the reaction mixture, which was then transformed into zwitterion **O** and attacked an isatin molecule. A synthesis of spiranes has been reported,<sup>134</sup> using a palladium catalyst containing *N,N*-dialkyldibenzo-*[d,f]*[1,3,2]dioxaphosphepine-6-amines, including ones with chiral groups at the nitrogen atom (Scheme 59).

Mohammadi and co-authors<sup>135</sup> described an interaction of isatin derivatives with aldehydes that was catalyzed by phosphoric acid and a tetrazole derivative, forming 3-hydroxyoxindoles **120**. The same publication also described the use of sterically congested phosphoric acids **121**, **122** as catalysts (Scheme 60).

The acids **121**, **122** were also used as catalysts for the reaction of some isatins with (2-aminoethyl)indoles, which produced the spirocyclic compounds **123** (Scheme 61).<sup>136</sup>


Substituted isatins were used in Michael reaction for the synthesis of compounds **124**, using chiral sterically congested phosphoric acids, such as compound **125**, for improving the enantioselectivity of the reaction (Scheme 62).<sup>137</sup>

Scheme 60




Synthesis of the biologically active spiro[indolin-3,2'-pyrrolidine] **126**, showing a moderate cytotoxic activity, was accomplished by Shi and coworkers<sup>138</sup> using chiral phosphorus-containing catalysts, analogous to structures **121** and **122** (Scheme 63).


Scheme 61



Scheme 62




Scheme 63




Methyl 3-bromo-2-(2-oxoindolin-3-ylidene)propanoates **127** reacted with methyl acrylate when catalyzed by triphenylphosphine and potassium carbonate under argon atmosphere at 120°C for 8 h, forming 3-spiro[cyclopent[2]-ene-1,3'-indolines] **128** in good yields.<sup>139</sup> Along with this compound, methyl 2-(2-oxoindolin-3-ylidene)propanoate **129** was also formed (Scheme 64).

Scheme 64




The isatins **1e,h,p** were used in a three-component Povarov reaction, catalyzed by the chiral phosphoric acid **121**.<sup>140</sup> It was noted that the initial intermediate was isatin-3-imine, which further reacted with hydroxystyrene. The obtained spiro[indoline-3,2'-quinolines] **130** showed high antifungal and antibacterial activity (Scheme 65).

Scheme 65



The reaction of isatin (**1a**) with phenols, naphthols, or dinaphthols in the presence of POCl<sub>3</sub> gave 2-oxoindoline derivatives **131**, containing a diaryloxyacetal fragment at position 3 (Scheme 66).<sup>141</sup>


Scheme 66



#### OTHER REACTIONS OF ISATIN WITH PHOSPHORUS COMPOUNDS


A reaction of isatin **1a** with bis(triphenylphosphine)-platinum dichloride in methanol in the presence of triethylamine led to the formation of complexes **132** with one or two heterocyclic fragments.<sup>142</sup> Gold-containing isatin derivatives **133** with N–Au bond were described in the work<sup>143</sup> (Scheme 67).

Scheme 67



The reaction of isatin (**1a**) with tetraphosphorus decasulfide in pyridine led to the formation of pentathiepin[6,7-*b*]indole **134** (Scheme 68).<sup>144,145</sup>


Scheme 68



The treatment of isatin with phosphorus pentachloride, followed by hydrolysis in aqueous methanol gave the alkaloid triptanthrine **135** (Scheme 69).<sup>146</sup>


The intermediate compound – 2-chloro-3*H*-indol-3-one **136** – can be obtained by the action of PCl<sub>5</sub><sup>147</sup> on isatin **1a**.

Scheme 69



Condensation of isatin **1a** with crown ether in the presence of phosphorus(V) oxide and methanesulfonic acid gave polymeric structures **137**, soluble in organic solvents, and capable of forming flexible, transparent films (Scheme 70).<sup>148</sup>

Scheme 70



The constant interest of chemists towards isatin derivatives is primarily linked to their high biological activity, including a whole family of alkaloids. This brief analysis of publications devoted to the interactions between isatin derivatives and phosphorus(III–V) compounds shows the considerable diversity of such chemical reactions: phosphorylation, various condensation and dimerization reactions, deoxygenation, and the formation of spirocyclic structures. A majority of the described transformations occurred at the activated carbonyl group at position 3 of the isatin molecule. A large volume of works have been devoted to the use of isatins as carbonyl components in cycloaddition reactions, which may occur by various mechanisms. Recent publications describe the preparation of compounds with a wider range of practical applications (catalyst ligands, polymeric materials, etc.). Despite the large number of publications where organophosphorus compounds have been used, only in rare cases the reaction mechanism has been actually investigated, rather than just postulated. Not many publications have been devoted to the synthesis of isatin

derivatives carrying organophosphorus fragments. Yet, taking into account the high biological activity of phosphorus compounds, new and interesting types of activity should be expected from such compounds, as already confirmed by the high antimicrobial and antifungal activity of phosphorus-containing hydrazones, obtained from isatin derivatives.<sup>108,109</sup> We should also note the increased interest of researchers towards deoxygenation reactions of various isatins in the presence of P(III) derivatives, since such reactions produce isoindigo derivatives of practical value. Generally, we can conclude that a further study of reactions between various phosphorus derivatives and isatins and their heterocyclic analogs holds a considerable promise both from the synthetic, as well as from mechanistic point of view.

## References

- Gribble, G. W. *Top. Heterocycl. Chem.* **2010**, *26*, 488.
- Taber, D. F.; Tirunahari, P. K. *Tetrahedron* **2011**, *67*, 7195.
- Shiri, M. *Chem. Rev.* **2012**, *112*, 3508.
- Kaushik, N. K.; Kaushik, N.; Attri, P.; Kumar, N.; Kim, C. H.; Verma, A. K.; Choi, E. H. *Molecules* **2013**, *18*, 6620.
- Ali, N. A. S.; Dar, B. A.; Pradhan, V.; Farooqui, M. *Mini. Rev. Med. Chem.* **2013**, *13*, 1792.
- Biswal, S.; Sahoo, U.; Sethy, S.; Kumar, H. K. S.; Banerjee, M. *Asian J. Pharm. Clinic. Res.* **2012**, *5*(1), 1.
- Sharma, V.; Kumar, P.; Pathaka, D. *J. Heterocycl. Chem.* **2010**, *47*, 491.
- Robb, M. J.; Ku, S.-Y.; Brunetti, F. G.; Hawker, C. J. *J. Polym. Sci. A: Polym. Chem.* **2013**, *51*, 1263.
- Pal, M.; Sharma, N. K.; Priyanka; Jha, K. K. *J. Adv. Sci. Res.* **2011**, *2*, 35.
- Vine, K. L.; Matesic, L.; Locke, J. M.; Ranson, M.; Skropeta, D. *Anti-Cancer Agents Med. Chem.* **2009**, *9*, 397.
- Patel, H.; Darji, N.; Pillai, J.; Patel, B. *Int. J. Drug Res. Tech.* **2012**, *2*, 225.
- Cerchiaro, G.; da Costa Ferreira, A. M. *J. Braz. Chem. Soc.* **2006**, *17*, 1473.
- Singh, G. S.; Desta, Z. Y. *Chem. Rev.* **2012**, *112*, 6104.
- Borad, M. A.; Bhoi, M. N.; Prajapati, N. P.; Patel, H. D. *Synth. Commun.* **2014**, *44*, 897.
- Lashgari, N.; Ziarani, G. M. *ARKIVOC* **2012**, (i), 277.
- Zhungleu, G. I.; Rechter, M. A. *Isatin and its Derivatives* [in Russian]; Shtiintsa: Kishinev, 1977.
- Silva, J. F. M.; Garden, S. J.; Pinto, A. C. *J. Braz. Chem. Soc.* **2001**, *12*, 273.
- Medvedev, A. E.; Goodwin, B.; Clow, A.; Halket, J.; Glover, V.; Sandler, M. *Biochem. Pharmacol.* **1992**, *44*, 590.
- Medvedev, A.; Buneeva, O.; Glover, V. *Biol.: Targets Ther.* **2007**, *1*, 151.
- Hamaue, N.; Yamazaki, N.; Minami, M.; Endo, T.; Hirahuji, M.; Monma, Y.; Togashi, H. *Gen. Pharmacol.* **1998**, *30*, 387.
- Pervez, H.; Iqbal, M. S.; Tahir, M. Y.; Nasim, F. H.; Choudhary, M. I.; Khan, K. M. *J. Enzyme Inhib. Med. Chem.* **2008**, *23*, 848.
- Sridhar, S. K.; Pandeya, S. N.; Stables, J. P.; Ramesh, A. *Eur. J. Pharm. Sci.* **2002**, *16*, 129.
- Verma, M.; Pandeya, S. N.; Singh, K. N.; Stables, J. P. *Acta Pharm.* **2004**, *54*, 49.



24. Kumar, S.; Dhar, D. N.; Saxena, P. N. *J. Sci. Ind. Res.* **2009**, *68*, 181.
25. McIntyre, I. M.; Norman, T. R. *J. Neural Transm.* **1990**, *79*, 35.
26. Chen, L.-R.; Wang, Y.-C.; Lin, Y. W.; Chou, S.-Y.; Chen, S.-F.; Liu, L. T.; Wu, Y.-T.; Kuo, C.-J.; Chen, T. S.-S.; Juang, S.-H. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 3058.
27. Medvedev, A. E.; Sandler, M.; Glover, V. *Life Sci.* **1998**, *62*, 2391.
28. Medvedev, A. E.; Clow, A.; Sandler, M.; Glover, V. *Biochem. Pharmacol.* **1996**, *52*, 385.
29. Gurevich, P. A.; Yaroshevskaya, V. A. *Chem. Heterocycl. Compd.* **2000**, *36*, 1361. [*Khim. Geterotsikl. Soedin.* **2000**, 1587.]
30. Gurevich, P. A.; Akhmetova, G. Z.; Gubaydullin, A. T.; Moskva, V. V.; Litvinov, I. A. *Zh. Obshch. Khim.* **1998**, *68*, 1570.
31. Akhmetova, G. Z.; Gurevich, P. A.; Moskva, V. V.; Arkhipov, V. P. *Zh. Obshch. Khim.* **1998**, *68*, 2055.
32. Maheshwara Rao, K. U.; Dinneswara Reddy, G.; Chung, C.-M. *Phosphorus, Sulfur Silicon Relat. Elem.* **2013**, *188*, 1104.
33. Shankar, J.; Karnakar, K.; Srinivas, B.; Nageswar, Y. V. D. *Tetrahedron Lett.* **2010**, *51*, 3938.
34. Peng, L.; Wang, L.; Bai, J.; Jia, L.; Yang, Q.; Huang, Q.; Xu, X.; Wang, L. *Tetrahedron Lett.* **2011**, *52*, 1157.
35. Nagarapu, L.; Mallepalli, R.; Nikhil Kumar, U.; Venkateswarlu, P.; Bantu, R.; Yeramanchi, L. *Tetrahedron Lett.* **2012**, *53*, 1699.
36. Mahran, M. R. H.; Khidre, M. D.; Abdou, W. M. *Phosphorus, Sulfur Silicon Relat. Elem.* **1995**, *101*, 17.
37. Hosseini-Sarvari, M.; Tavakolian, M. *Can. J. Chem.* **2013**, *91*, 1117.
38. Deng, T.; Wang, H.; Cai, C. *Org. Biomol. Chem.* **2014**, *12*, 5843.
39. Wang, L.; Yao, Z.; Xu, F.; Shen, Q. *Heteroat. Chem.* **2012**, *23*, 449.
40. Mustafa, A.; Sidky, M. M.; Spoliman, F. M. *Tetrahedron* **1966**, *22*, 393.
41. Sharma, D.; Bansal, R. K. *J. Indian Chem. Soc.* **1990**, *67*, 29.
42. Abdou, W. M.; Abd El-Rahman, N. M.; Mahran, M. R. H. *J. Prakt. Chem.* **1989**, *331*, 906.
43. Riisalu, Kh. Y.; Vasilev, V. V.; Ionin, B. I. *Zh. Obshch. Khim.* **1984**, *54*, 563.
44. Riisalu, Kh. Y.; Vasilev, V. V.; Ionin, B. I. *Zh. Obshch. Khim.* **1985**, *55*, 2237.
45. Akhmetova, G. Z.; Gurevich, P. A.; Moskva, V. V. *Zh. Obshch. Khim.* **1998**, *68*, 2057.
46. Musin, L. I.; Bogdanov, A. V.; Krivolapov, D. B.; Dobrynin, A. B.; Litvinov, I. A.; Mironov, V. F. *Russ. J. Org. Chem.* **2014**, *50*, 822. [*Zh. Org. Khim.* **2014**, *50*, 839.]
47. Razumov, A. I.; Gurevich, P. A.; Nurtidinov, S. Kh.; Muslimov, S. A.; Tyl'nova, L. M. *Zh. Obshch. Khim.* **1977**, *47*, 1421.
48. Lathourakis, G. E.; Litinas, K. E. *J. Chem. Soc., Perkin Trans. 1* **1996**, 491.
49. Bogdanov, A. V.; Mironov, V. F.; Musin, L. I.; Buzykin, B. I.; Kononov, A. I. *Russ. J. Gen. Chem.* **2008**, *78*, 1977. [*Zh. Obshch. Khim.* **2008**, *78*, 1741.]
50. Bogdanov, A. V.; Mironov, V. F.; Musin, L. I.; Musin, R. Z. *Synthesis* **2010**, 3268.
51. Bogdanov, A. V.; Mironov, V. F.; Musin, L. I.; Musin, R. Z.; Krivolapov, D. B.; Litvinov, I. A. *Monatsh. Chem.* **2011**, *142*, 81.
52. Bogdanov, A. V.; Musin, L. I.; Mironov, V. F. *Russ. J. Gen. Chem.* **2011**, *81*, 964. [*Zh. Obshch. Khim.* **2011**, *81*, 877.]
53. Bogdanov, A. V.; Bukharov, S. V.; Oludina, Y. N.; Musin, L. I.; Nugumanova, G. N.; Syakaev, V. V.; Mironov, V. F. *ARKIVOC* **2013**, (iii), 424.
54. Bogdanov, A. V.; Mironov, V. F.; Sinyashin, O. G. *Russ. J. Org. Chem.* **2014**, *50*, 906. [*Zh. Org. Khim.* **2014**, *50*, 921.]
55. Bogdanov, A. V.; Musin, L. I.; Il'in, A. V.; Mironov, V. F. *J. Heterocycl. Chem.* **2014**, *51*, 1027.
56. Bogdanov, A. V.; Pashirova, T. N.; Musin, L. I.; Krivolapov, D. B.; Zaharova, L. Y.; Mironov, V. F.; Kononov, A. I. *Chem. Phys. Lett.* **2014**, *594*, 69.
57. Muslin, L. I.; Kutuzova, T. A.; Bogdanov, A. V. *Vestn. KGTU* **2014**, *17*(22), 50.
58. Ashraf, R. S.; Kronemeijer, A. J.; James, D. I.; Siringhaus, H.; McCulloch, I. *Chem. Commun.* **2012**, 3939.
59. Kleebblatt, D.; Siyo, B.; Hein, M.; Iaroshenko, V. O.; Iqbal, J.; Villinger, A.; Langer, P. *Org. Biomol. Chem.* **2013**, *11*, 886.
60. Xu, S.; Ai, N.; Zheng, J.; Zhao, N.; Lan, Z.; Wen, L.; Wang, X.; Pei, J.; Wan, X. *RSC Adv.* **2015**, *5*, 8340.
61. El-Kateb, A. A.; Hennawy, I. T.; Shabana, R.; Osman, F. H. *Phosphorus, Sulfur Silicon Relat. Elem.* **1984**, *20*, 329.
62. Dasari, R. R.; Dindar, A.; Lo, C. K.; Wang, C.-Y.; Quinton, C.; Singh, S.; Barlow, S.; Fuentes-Hernandez, C.; Reynolds, J. R.; Kippelen, B.; Marder, S. R. *Phys. Chem. Chem. Phys.* **2014**, *16*, 19345.
63. Guang, J.; Guo, Q.; Zhao, J. C.-G. *Org. Lett.* **2012**, *14*, 3174.
64. Singh, M. S.; Mishra, G. G.; Mehrotra, K. N. *Phosphorus, Sulfur Silicon Relat. Elem.* **1991**, *63*, 177.
65. Disteldorf, W.; Regitz, M. *Liebigs Ann. Chem.* **1976**, 225.
66. Regitz, M.; Disteldorf, W.; Eckstein, U.; Weber, B. *Tetrahedron Lett.* **1972**, *13*, 3979.
67. Poschenrieder, H.; Stachel, H.-D. *J. Heterocycl. Chem.* **1995**, *32*, 1457.
68. Tatarinov, D. A.; Bogdanov, A. V.; Buzykin, B. I.; Mironov, V. F. *Russ. J. Org. Chem.* **2014**, *50*, 518. [*Zh. Org. Khim.* **2014**, *50*, 529.]
69. Razumov, A. I.; Gurevich, P. A.; Muslimov, S. A.; Usacheva, V. G. *Zh. Obshch. Khim.* **1976**, *46*, 2381.
70. Ammetto, I.; Gasperi, T.; Loreto, M. A.; Migliorini, A.; Palmarelli, F.; Tardella, P. A. *Eur. J. Org. Chem.* **2009**, 6189.
71. Razumov, A. I.; Yarmukhametova, D. Kh.; Kudryavtsev, B. V.; Gurevich, P. A.; Muslimov, S. A. *Zh. Obshch. Khim.* **1978**, *48*, 228.
72. Shimazawa, R.; Kuriyama, M.; Shirai, R. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 3350.
73. Osman, F. H.; El-Samahy, F. A. *Tetrahedron* **2000**, *56*, 1863.
74. Osman, F. H.; El-Samahy, F. A. *Phosphorus, Sulfur Silicon Relat. Elem.* **1998**, *134*, 437.
75. Chen, Z.; Fan, J.; Kende, A. S. *J. Org. Chem.* **2004**, *69*, 79.
76. Kaku, H.; Takuwa, T.; Kageyama, M.; Nozawa, K.; Doihara, H. EP Patent 2261206.
77. Roth, G. J.; Heckel, A.; Walter, R.; Tontsch-Grunt, U.; Spevak, W.; Van Meel, J. C. A. US Patent 6794395.
78. He, Y.; Jiang, T.; Kuhen, K. L.; Ellis, D. A.; Wu, B.; Wu, T. Y.-H.; Bursulaya, B. WO Patent 2004037247.
79. Baba, K.; Kozawa, M.; Hata, K.; Ishida, T.; Inoue, M. *Chem. Pharm. Bull.* **1981**, *29*, 2182.

80. Parvatkar, P. T.; Tilve, S. G. *Tetrahedron Lett.* **2011**, *52*, 6594.
81. Sassatelli, M.; Debiton, É.; Aboab, B.; Prudhomme, M.; Moreau, P. *Eur. J. Med. Chem.* **2006**, *41*, 709.
82. Bouchikhi, F.; Rossignol, E.; Sancelme, M.; Aboab, B.; Anizon, F.; Fabbro, D.; Prudhomme, M.; Moreau, P. *Eur. J. Med. Chem.* **2008**, *43*, 2316.
83. Messaoudi, S.; Sancelme, M.; Polard-Housset, V.; Aboab, B.; Moreau, P.; Prudhomme, M. *Eur. J. Med. Chem.* **2004**, *39*, 453.
84. Huang, A.; Kodanko, J. J.; Overman, L. E. *J. Am. Chem. Soc.* **2004**, *126*, 14043.
85. Kraus, G. A.; Guo, H. *Org. Lett.* **2008**, *10*, 3061.
86. Coda, A. C.; Desimoni, G.; Quadrelli, P.; Riguetti, P. P.; Tacconi G. *Gazz. Chim. Ital.* **1987**, *117*, 301.
87. Eberle, M. K.; Kahle, G. G.; Shapiro, M. J. *J. Org. Chem.* **1982**, *47*, 2210.
88. Freeman, D. B.; Holubec, A. A.; Weiss, M. W.; Dixon, J. A.; Kakefuda, A.; Ohtsuka, M.; Inoue, M.; Vaswani, R. G.; Ohki, H.; Doan, B. D.; Reisman, S. E.; Stoltz, B. M.; Day, J. J.; Tao, R. N.; Dieterich, N. A.; Wood, J. L. *Tetrahedron* **2010**, *66*, 6647.
89. Majik, M. S.; Rodrigues, C.; Mascarenhas, S.; D'Souza, L. *Bioorg. Chem.* **2014**, *54*, 89.
90. Kozminykh, V. O.; Lomidze, K. Sh.; Kozminykh, E. N.; Berezin, A. N. *Chem. Heterocycl. Compd.* **2004**, *40*, 521. [*Khim. Geterotsikl. Soedin.* **2004**, 619.]
91. Jiang, T.; Kuhen, K. L.; Wolff, K.; Yin, H.; Bieza, K.; Caldwell, J.; Bursulaya, B.; Wu, T. Y.-H.; He, Y. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 2105.
92. Nakazaki A.; Mori A.; Kobayashi S.; Nishikawa T. *Tetrahedron Lett.* **2012**, *53*, 7131.
93. Kozminykh, E. N.; Berezina, E. S.; Kozminykh, V. O. *Zh. Obshch. Khim.* **1996**, *66*, 1128.
94. Soliman, F. M.; Khalil, K. M.; Said, M. M.; Maigali, S. S. *Heterocycl. Commun.* **2002**, *8*, 451.
95. Alizadeh, A.; Mokhtari, J. *Tetrahedron* **2011**, *67*, 3519.
96. Alizadeh, A.; Mokhtari, J. *Helv. Chim. Acta* **2013**, *96*, 124.
97. Alizadeh, A.; Mokhtari, J. *Helv. Chim. Acta* **2011**, *94*, 1315.
98. Zurwerra, D.; Wullschlegler, C. W.; Altmann, K.-H. *Angew. Chem., Int. Ed.* **2010**, *49*, 6936.
99. Hughes, C. C.; Fenical, W. *J. Am. Chem. Soc.* **2010**, *132*, 2528.
100. Liu, Y.; Zhou, J. *Chem. Commun.* **2013**, 4421.
101. Yan, W.; Wang, D.; Feng, J.; Li, P.; Zhao, D.; Wang, R. *Org. Lett.* **2012**, *14*, 2512.
102. Adib, M.; Sheikhi, E.; Kavooosi, A.; Bijanzadeh, H. R. *Synthesis* **2010**, 4082.
103. Gasperi, T.; Loreto, M. A.; Migliorini, A.; Ventura, C. *Eur. J. Org. Chem.* **2011**, 385.
104. Falsone, G.; Cateni, F.; El-Alali, A.; Papaioannou, A.; Ravalico, L.; Furlani, A. *Pharm. Pharmacol. Lett.* **1992**, *2*, 104.
105. Falsone, G.; Cateni, F.; Denardo, M. M.; Darai, M. M. *Z. Naturforsch.* **1993**, *48 b*, 1391.
106. Meanwell, N. A.; Roth, H. R.; Smith, E. C. R.; Wedding, Kim Wright, J. J. *J. Org. Chem.* **1991**, *56*, 6897.
107. Jagadeeswara Rao, P.; Bhawani Aishwarya, K. S.; Ishrath Begum, D.; Ravindranath, L. K. *Pharma Chem.* **2012**, *4*, 1935.
108. Bhawani Aishwarya, K. S.; Jagadeeswara Rao, P.; Spoorthy, Y. N.; Ishrath Begum, D.; Ravindranath, L. K. *J. Chem. Pharm. Res.* **2012**, *4*, 4052.
109. Bagrov, F. V.; Kolyamshin, O. A.; Bagrov, D. F. *Russ. J. Gen. Chem.* **1999**, *69*, 901. [*Zh. Obshch. Khim.* **1999**, *69*, 938.]
110. Esmaeili, A. A.; Amini, S.; Bodaghi, A. *Synlett* **2007**, 1452.
111. Esmaili, A. A.; Bodaghi, A. *Tetrahedron* **2003**, *59*, 1169.
112. Azizian, J.; Karimi, A. R.; Arefrad, H.; Mohammadi, A. A.; Mohammadzadeh, M. R. *Monatsh. Chem.* **2004**, *135*, 729.
113. Yavari, I.; Hossaini, Z.; Sabbaghan, M.; Ghazanfarpour-Darjani, M. *Tetrahedron* **2007**, *63*, 9423.
114. Ziyaadini, M.; Maghsoodlou, M. T.; Hazeri, N.; Habibi-Khorassani, S. M. *Monatsh. Chem.* **2012**, *143*, 1681.
115. Marandi, G.; Maghsoodlou, M. T.; Hazeri, N.; Heydari, R.; Habibi-Khorassani, S. M.; Torbati, N. A.; Sajadikhah, S. S.; Saravani, D.; Rakhshanipour, M.; Gholamipour, S.; Rostami-Charati, F.; Skelton, B. W.; Makha, M.; Zare, Z.; Lashkari, M. *Heteroat. Chem.* **2011**, *22*, 630.
116. Yavari, I.; Dehghan, Sh.; Alborzi, A. R.; Mohtat, B. *Polish J. Chem.* **2005**, *79*, 845.
117. Baharfar, R.; Heydari, A.; Saffarian, N. *J. Chem. Res., Synop.* **2001**, 536.
118. Nair, V.; Biju, A. T.; Vinod, A. U.; Suresh, E. *Org. Lett.* **2005**, *7*, 5139.
119. Yavari, I.; Hossaini, Z.; Karimi, E. *Monatsh. Chem.* **2007**, *138*, 1267.
120. Al-Resayes, S.-I. *Spectrosc. Lett.* **1999**, *32*, 315.
121. Shakibaei, G. I.; Feiz, A.; Ghahremanzadeh, R.; Bazgir, A. *Chem. Pharm. Bull., Int. Ed.* **2010**, *58*, 896.
122. Shakibaei, G. I.; Samadi, S.; Ghahremanzadeh, R.; Bazgir, A. *J. Comb. Chem.* **2010**, *12*, 295.
123. Hosseini-Sarvari, M.; Tavakolian, M. *New J. Chem.* **2012**, *36*, 1014.
124. Matveeva, E. D.; Podrugina, T. A.; Prisyajnoy, M. V.; Zefirov, N. S. *Rus. Chem. Bull.* **2006**, *55*, 1209. [*Izv. Akad. Nauk, Ser. Khim.* **2006**, 1164.]
125. Chavannavar, A. P.; Oliver, A. G.; Ashfeld, B. L. *Chem. Commun.* **2014**, *50*, 10853.
126. Romanova, I. P.; Bogdanov, A. V.; Mironov, V. F.; Shaikhutdinova, G. R.; Larionova, O. A.; Latypov, Sh. K.; Balandina, A. A.; Yakhvarov, D. G.; Gubaidullin, A. T.; Saifina, A. F.; Sinyashin, O. G. *J. Org. Chem.* **2011**, *76*, 2548.
127. Romanova, I. P.; Shaikhutdinova, G. R.; Yusupova, G. G.; Bogdanov, A. V.; Musin, L. I.; Yakhvarov, D. G.; Valitov, M. I.; Nizameev, I. R.; Mironov, V. F.; Sinyashin, O. G. *Rus. Chem. Bull., Int. Ed.* **2011**, *60*, 867. [*Izv. Akad. Nauk, Ser. Khim.* **2011**, 847.]
128. Romanova, I. P.; Bogdanov, A. V.; Izdelieva, I. A.; Trukhanov, V. A.; Shaikhutdinova, G. R.; Yakhvarov, D. G.; Latypov, Sh. K.; Mironov, V. F.; Dyakov, V. A.; Golovnin, I. V.; Parashuk, D. Yu.; Sinyashin, O. G. *Beilstein J. Org. Chem.* **2014**, *10*, 1121.
129. Bogdanov, A. V.; Yusupova, G. G.; Romanova, I. P.; Latypov, S. K.; Krivolapov, D. B.; Mironov, V. F.; Sinyashin, O. G. *Synthesis* **2013**, 668.
130. Valitov, M. I.; Romanova, I. P.; Gromchenko, A. A.; Shaikhutdinova, G. R.; Yakhvarov, D. G.; Bruevich, V. V.; Dyakov, V. A.; Sinyashin, O. G.; Parashuk, D. Yu. *Sol. Energy Mater. Sol. Cells* **2012**, *103*, 48.
131. Lian, Z.; Shi, M. *Eur. J. Org. Chem.* **2012**, 581.
132. Lian, Z.; Wei, Y.; Shi, M. *Tetrahedron* **2012**, *68*, 2401.

133. Zhang, X.; Cao, S.; Wei, Y.; Shi, M. *Chem. Commun.* **2011**, 47, 1548.
134. Shintani, R.; Hayashi, S.; Murakami, M.; Takeda, M.; Hayashi, T. *Org. Lett.* **2009**, 11, 3754.
135. Mohammadi, S.; Heiran, R.; R. P. Herrera, Márques-López, E. *ChemCatChem* **2013**, 5, 2131.
136. Badillo, J. J.; Silva-García, A.; Shupe, B. H.; Fettinger, J. C.; Franz, A. K. *Tetrahedron Lett.* **2011**, 52, 5550.
137. Liu, L.; Wu, D.; Li, X.; Wang, S.; Li, H.; Li, J.; Wang, W. *Chem. Commun.* **2012**, 48, 1692.
138. Shi, F.; Tao, Z.; Luo, S.; Tu, S.; Gong, L. *Chem.–Eur. J.* **2012**, 18, 6885.
139. Selvakumar, K.; Vaithyanathana, V.; Shanmugam, P. *Chem. Commun.* **2010**, 46, 2826.
140. Shi, F.; Xing, G.; Zhu, R.; Tan, W.; Tu, S. *Org. Lett.* **2013**, 15, 128.
141. Gabel', Yu. O.; Zubarovskii, V. M. *Zh. Obshch. Khim.* **1937**, 7, 305.
142. Law, J. M.; Henderson, W.; Nicholson, B. K. *J. Chem. Soc., Dalton Trans.* **1997**, 24, 4587.
143. Churakov, A. V.; Kuz'mina, L. G.; Howard, J. A. K.; Grandberg, K. I. *Acta Crystallogr., Sect. C: Cryst. Struct. Commun.* **1998**, C54, 54.
144. Bergman, J.; Stålhandske, K. *Tetrahedron Lett.* **1994**, 35, 5279.
145. Janosik, T.; Bergman, J.; Stensland, B.; Stålhandske, C. *J. Chem. Soc., Perkin Trans. 1* **2002**, 330.
146. Cornforth, J.; Hitchcock, P. B.; Rozos, P. *J. Chem. Soc., Perkin Trans. 1* **1996**, 2787.
147. Sawiski, E.; Stanley, T. W.; Hauser, T. R.; Barry, R. *Anal. Chem.* **1959**, 31, 1664.
148. Zolotukhin, M. G.; Hernández, M. G.; Lopez, A. M.; Fomina, L.; Cedillo, G.; Nogales, A.; Ezquerra, T.; Rueda, D.; Colquhoun, H. M.; Fromm, K. M.; Ruiz-Treviño, A.; Ree, M. *Macromolecules* **2006**, 39, 4696.